Tobacco-Cessation Interventions for TB and HIV Care
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals wiht obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated notable weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the trial also showed a significant reduction in the development of type 2 diabetes among participants.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| New-Onset Type 2 Diabetes | 15.0 | 25.3 | 0.61 |
Who is Affected? understanding the Patient Population
This finding is especially relevant for individuals already diagnosed with established cardiovascular disease. The SELECT trial specifically enrolled participants with a history of heart attack, stroke, or peripheral artery disease. It does *not* necessarily mean that semaglutide is unsafe for everyone; the risk-benefit profile may differ significantly in individuals without pre-existing heart conditions. The average age of participants was 61, and approximately 40% were women.
Why Does This Happen? Potential Mechanisms at Play
The exact reasons for the increased cardiovascular risk are still under investigation. Several hypotheses are being explored, including the possibility that rapid weight loss itself can sometimes destabilize existing cardiovascular conditions. Another theory suggests that semaglutide might have direct effects on the heart, although this remains speculative. Further research is needed to elucidate the underlying mechanisms.
